Dr. Simon Thomson, MBBS, FRCA, FIPP, International Neuromodulation Society (INS) president from 2009 – June 2015 is a consultant in neuromodulation and pain management at Basildon and Thurrock University NHS Trust, as well as serving on the staff of Addenbrookes Hospital, Cambridge. He presented a talk about the National Institute for Health and Care Excellence (NICE) technology assessment for spinal cord stimulation in England and Wales. The assessment concluded that spinal cord stimulation for neuropathic pain is clinically effective at an achievable cost, making it mandatory for all health bodies to commission it appropriately due to its demonstrated cost-effectiveness.
Disclaimer: The International Neuromodulation Society (INS) provides videotaped talks by physicians and patients about neuromodulation therapy on its YouTube channel. INS produced videos of talks presented at a public event in 2015 that was jointly organized by the INS and the Canadian Neuromodulation Society. The information presented should not be used as a substitute for medical treatment and advice.
Share this Video
Related Videos In Neuropathic Pain
Erika Petersen, AAN 2021: Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy
We were delighted to speak with Prof. Erika Petersen (University of Arkansas for Medical Sciences, Little Rock, AR, USA) around the six month results from the SENZA-PDN study. The abstract entitled: ‘Sustained Benefits for 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy—Six Month Results from a Multicenter Randomized Controlled Trial’ was presented at […]
José A. López García, EAN 2021: Clinical Development of SAN711, and its Potential to Treat Neuropathic Pain
It was a pleasure to meet with José A. López García (University of Alcalá, Alcalá de Henares, Spain) to discuss the clinical development of SAN711, a selective GABAA α3 receptor positive allosteric modulator for the potential treatment of neuropathic pain. The abstract entitled: ‘SAN711 a selective GABAA α3 receptor positive allosteric modulator as a novel […]
Raili Kauppinen, EAN 2020 – ENVISION Study in Patients With Acute Hepatic Porphyria
Raili Kauppinen (University Hospital of Helsinki, Finland) shares key findings and insights into the ENVISION study, which evaluated the efficacy and safety of givosiran, a subcutaneously administered RNA interference therapeutic targeting aminolevulinic acid synthase 1, in patients with acute hepatic porphyrias (ClinicalTrials.gov Identifier: NCT03338816). Questions 1. Could you give us a brief overview of acute […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!